We’ve recently updated our valuation analysis.

Guardant Health Valuation

Is GH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GH?

Other financial metrics that can be useful for relative valuation.

GH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.5x
Enterprise Value/EBITDA-11.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does GH's PS Ratio compare to its peers?

The above table shows the PS ratio for GH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.8x
OPCH Option Care Health
1.3x8.3%US$5.2b
AMN AMN Healthcare Services
1x-12.0%US$5.3b
SGFY Signify Health
6.5x18.3%US$6.7b
OSH Oak Street Health
2.4x27.2%US$4.7b
GH Guardant Health
11.9x23.3%US$5.1b

Price-To-Sales vs Peers: GH is expensive based on its Price-To-Sales Ratio (11.9x) compared to the peer average (2.8x).


Price to Earnings Ratio vs Industry

How does GH's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.3%
n/an/an/a

Price-To-Sales vs Industry: GH is expensive based on its Price-To-Sales Ratio (11.9x) compared to the US Healthcare industry average (1x)


Price to Sales Ratio vs Fair Ratio

What is GH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.9x
Fair PS Ratio7.3x

Price-To-Sales vs Fair Ratio: GH is expensive based on its Price-To-Sales Ratio (11.9x) compared to the estimated Fair Price-To-Sales Ratio (7.3x).


Share Price vs Fair Value

What is the Fair Price of GH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GH's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$50.07
US$78.80
+57.4%
14.2%US$99.00US$50.00n/a15
Nov ’23US$49.59
US$92.87
+87.3%
21.4%US$130.00US$50.00n/a15
Oct ’23US$53.83
US$95.85
+78.1%
21.8%US$130.00US$65.00n/a13
Sep ’23US$49.07
US$95.85
+95.3%
21.8%US$130.00US$65.00n/a13
Aug ’23US$48.38
US$99.58
+105.8%
19.5%US$130.00US$65.00n/a12
Jul ’23US$43.66
US$111.75
+156.0%
23.4%US$165.00US$65.00n/a12
Jun ’23US$38.65
US$116.00
+200.1%
19.9%US$165.00US$85.00n/a11
May ’23US$61.70
US$124.64
+102.0%
16.5%US$165.00US$91.00n/a11
Apr ’23US$73.04
US$125.10
+71.3%
16.8%US$165.00US$91.00n/a10
Mar ’23US$66.33
US$126.45
+90.6%
16.2%US$165.00US$91.00n/a11
Feb ’23US$72.96
US$154.75
+112.1%
18.5%US$185.00US$91.00n/a12
Jan ’23US$100.02
US$160.17
+60.1%
14.7%US$185.00US$91.00n/a12
Dec ’22US$97.66
US$160.17
+64.0%
14.7%US$185.00US$91.00n/a12
Nov ’22US$120.43
US$161.31
+33.9%
15.2%US$185.00US$91.00US$49.5913
Oct ’22US$107.51
US$161.31
+50.0%
15.2%US$185.00US$91.00US$53.8313
Sep ’22US$131.51
US$161.31
+22.7%
15.2%US$185.00US$91.00US$49.0713
Aug ’22US$109.80
US$164.00
+49.4%
15.0%US$195.00US$91.00US$48.3813
Jul ’22US$126.85
US$164.69
+29.8%
15.3%US$195.00US$89.00US$43.6613
Jun ’22US$119.12
US$167.67
+40.8%
16.3%US$195.00US$89.00US$38.6512
May ’22US$158.98
US$170.64
+7.3%
16.9%US$195.00US$89.00US$61.7011
Apr ’22US$156.99
US$170.64
+8.7%
16.9%US$195.00US$89.00US$73.0411
Mar ’22US$152.14
US$170.45
+12.0%
17.9%US$195.00US$83.00US$66.3311
Feb ’22US$155.41
US$156.36
+0.6%
18.8%US$190.00US$83.00US$72.9611
Jan ’22US$128.88
US$137.78
+6.9%
7.9%US$155.00US$120.00US$100.029
Dec ’21US$121.23
US$130.78
+7.9%
4.9%US$145.00US$120.00US$97.669
Nov ’21US$106.66
US$116.78
+9.5%
7.4%US$130.00US$100.00US$120.439

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies